Properdin in complement activation and tissue injury

Molecular Immunology

Volumn 56, Issue 3, 2013, Pages 191-198

  Lesher, Allison M ^a   Nilsson, Bo ^b   Song, Wen Chao ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

Alternative pathway; C3 glomerulopathy; Complement therapeutics; Properdin

Indexed keywords

COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5B; PROPERDIN;

ANTIBODY PRODUCTION; AUTOIMMUNE DISEASE; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; GLOMERULONEPHRITIS; GLOMERULOPATHY; HOST CELL; HUMAN; KIDNEY INJURY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; TISSUE INJURY;

ALTERNATIVE PATHWAY; C3 GLOMERULOPATHY; COMPLEMENT THERAPEUTICS; PROPERDIN;

ANIMALS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; COMPLEMENT ACTIVATION; COMPLEMENT PATHWAY, ALTERNATIVE; COMPLEMENT SYSTEM PROTEINS; HUMANS; PROPERDIN;

EID: 84880792563     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2013.06.002     Document Type: Review

References (76)

1. Agarwal S., Ferreira V.P., Cortes C., Pangburn M.K., Rice P.A., Ram S. An evaluation of the role of properdin in alternative pathway activation on Neisseria meningitidis and Neisseria gonorrhoeae. Journal of Immunology 2010, 185:507-516.
2. Agarwal S., Specht C.A., Haibin H., Ostroff G.R., Ram S., Rice P.A., Levitz S.M. Linkage specificity and role of properdin in activation of the alternative complement pathway by fungal glycans. mBio 2011, 2.
3. Camous L., Roumenina L., Bigot S., Brachemi S., Fremeaux-Bacchi V., Lesavre P., Halbwachs-Mecarelli L. Complement alternative pathway acts as a positive feedback amplification of neutrophil activation. Blood 2011, 117:1340-1349.
4. Clardy C.W., Forristal J., Strife C.F., West C.D. A properdin dependent nephritic factor slowly activating C3, C5, and C9 in membranoproliferative glomerulonephritis, types I and III. Clinical Immunology and Immunopathology 1989, 50:333-347.
5. Cortes C., Ferreira V.P., Pangburn M.K. Native properdin binds to Chlamydia pneumoniae and promotes complement activation. Infection and Immunity 2011, 79:724-731.
6. Daha M.R. Unexpected role for properdin in complement C3 glomerulopathies. Journal of the American Society of Nephrology 2013, 24:5-7.
7. de Cordoba S.R., de Jorge E.G. Translational mini-review series on complement factor H: genetics and disease associations of human complement factor H. Clinical and Experimental Immunology 2008, 151:1-13.
8. Dimitrova P., Ivanovska N., Belenska L., Milanova V., Schwaeble W., Stover C. Abrogated RANKL expression in properdin-deficient mice is associated with better outcome from collagen-antibody-induced arthritis. Arthritis Research and Therapy 2012, 14:R173.
9. Dimitrova P., Ivanovska N., Schwaeble W., Gyurkovska V., Stover C. The role of properdin in murine zymosan-induced arthritis. Molecular Immunology 2010, 47:1458-1466.
10. Dunkelberger J.R., Song W.C. Complement and its role in innate and adaptive immune responses. Cell Research 2010, 20:34-50.
11. Fakhouri F., Fremeaux-Bacchi V., Noel L.H., Cook H.T., Pickering M.C. C3 glomerulopathy: a new classification. Nature Reviews Nephrology 2010, 6:494-499.
12. Farries T.C., Finch J.T., Lachmann P.J., Harrison R.A. Resolution and analysis of 'native' and 'activated' properdin. Biochemical Journal 1987, 243:507-517.
13. Farries T.C., Lachmann P.J., Harrison R.A. Analysis of the interactions between properdin, the third component of complement (C3), and its physiological activation products. Biochemical Journal 1988, 252:47-54.
14. Fearon D.T., Austen K.F. Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase. Journal of Experimental Medicine 1975, 142:856-863.
15. Ferreira V.P., Cortes C., Pangburn M.K. Native polymeric forms of properdin selectively bind to targets and promote activation of the alternative pathway of complement. Immunobiology 2010, 215:932-940.
16. Fijen C.A.P., van den Bogaard R., Schipper M., Mannens M., Schlesinger M., Nordin F.G., Dankert J., Daha M.R., Sjöholm A.G., Truedsson L., Kuijper E.J. Properdin deficiency: molecular basis and disease association. Molecular Immunology 1999, 36:863-867.
17. Gaarkeuken H., Siezenga M.A., Zuidwijk K., van Kooten C., Rabelink T.J., Daha M.R., Berger S.P. Complement activation by tubular cells is mediated by properdin binding. American Journal of Physiology. Renal Physiology 2008, 295:F1397-F1403.
18. Gotze O., Muller-Eberhard H.J. The role of properdin in the alternate pathway of complement activation. Journal of Experimental Medicine 1974, 139:44-57.
19. Gou S.J., Yuan J., Chen M., Yu F., Zhao M.H. Circulating complement activation in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. Kidney International 2013, 83:129-137.
20. Gulati S., Agarwal S., Vasudhev S., Rice P.A., Ram S. Properdin is critical for antibody-dependent bactericidal activity against Neisseria gonorrhoeae that recruit C4b-binding protein. Journal of Immunology 2012, 188:3416-3425.
21. Gupta-Bansal R., Parent J.B., Brunden K.R. Inhibition of complement alternative pathway function with anti-properdin monoclonal antibodies. Molecular Immunology 2000, 37:191-201.
22. Harboe M., Garred P., Karlstrom E., Lindstad J.K., Stahl G.L., Mollnes T.E. The down-stream effects of mannan-induced lectin complement pathway activation depend quantitatively on alternative pathway amplification. Molecular Immunology 2009, 47:373-380.
23. Harboe M., Garred P., Lindstad J.K., Pharo A., Muller F., Stahl G.L., Lambris J.D., Mollnes T.E. The role of properdin in zymosan- and Escherichia coli-induced complement activation. Journal of Immunology 2012, 189:2606-2613.
24. Heinen S., Pluthero F.G., van Eimeren V.F., Quaggin S.E., Licht C. Monitoring and modeling treatment of atypical hemolytic uremic syndrome. Molecular Immunology 2013, 54:84-88.
25. Holers V.M. The spectrum of complement alternative pathway-mediated diseases. Immunological Reviews 2008, 223:300-316.
26. Hourcade D.E. The role of properdin in the assembly of the alternative pathway C3 convertases of complement. Journal of Biological Chemistry 2006, 281:2128-2132.
27. Ingwer I., Petersen B.H., Brooks G. Serum bactericidal action and activation of the classic and alternate complement pathways by Neisseria gonorrhoeae. The Journal of Laboratory and Clinical Medicine 1978, 92:211-220.
28. Kemper C., Atkinson J.P., Hourcade D.E. Properdin: emerging roles of a pattern-recognition molecule. Annual Review of Immunology 2010, 28:131-155.
29. Kemper C., Mitchell L.M., Zhang L., Hourcade D.E. The complement protein properdin binds apoptotic T cells and promotes complement activation and phagocytosis. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:9023-9028.
30. Kimura Y., Miwa T., Zhou L., Song W.C. Activator-specific requirement of properdin in the initiation and amplification of the alternative pathway complement. Blood 2008, 111:732-740.
31. Kimura Y., Zhou L., Miwa T., Song W.C. Genetic and therapeutic targeting of properdin in mice prevents complement-mediated tissue injury. Journal of Clinical Investigation 2010, 120:3545-3554.
32. Lachmann P.J. The amplification loop of the complement pathways. Advances in Immunology 2009, 104:115-149.
33. Lesher A.M., Zhou L., Kimura Y., Sato S., Gullipalli D., Herbert A.P., Barlow P.N., Eberhart H.U., Skerka C., Zipfel P.F., Hamano T., Miwa T., Tung K.S.W.C.S. Combination of factor H mutation and properdin deficiency causes severe C3 glomerulopathy. Journal of the American Society of Nephrology 2013, 24:53-65.
34. Liszewski M.K., Farries T.C., Lubun D.M., Rooney I.A., Atkinson J.P., Frank J.D. Control of the Complement System. Advances in Immunology 1996, 61:201-283.
35. Martinez-Barricarte R., Heurich M., Valdes-Canedo F., Vazquez-Martul E., Torreira E., Montes T., Tortajada A., Pinto S., Lopez-Trascasa M., Morgan B.P., Llorca O., Harris C.L., Rodiguez de Cordoba S. Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation. Journal of Clinical Investigation 2010, 120:3702-3712.
36. Maves K.K., Weiler J.M. Properdin: approaching four decades of research. Immunologic Research 1993, 12:233-243.
37. Medicus R.G., Gotze O., Muller-Eberhard H.J. Alternative pathway of complement: recruitment of precursor properdin by the labile C3/C5 convertase and the potentiation of the pathway. Journal of Experimental Medicine 1976, 144:1076-1093.
38. Medicus R.G., Götze O., Müller-Eberhard H.J. Activation of Properdin (P) and Assembly and Regulation of the Alternative Pathway C5 Convertase. Journal of Immunology 1976, 116:1741-1742.
39. Miwa T., Sato S., Gullipalli D., Nangaku M., Song W.C. Blocking properdin and the alternative pathway complement ameliorates renal ischemia reperfusion injury in decay-accelerating factor and CD59 double knockout mice. Journal of Immunology 2012, 189:5434-5441.
40. Miwa T., Zhou L., Hilliard B., Molina H., Song W.C. Crry, but not CD59 and DAF, is indispensable for murine erythrocyte protection in vivo from spontaneous complement attack. Blood 2002, 99:3707-3716.
41. Mollnes T.E., Ng Y.C., Peters D.K., Lea T., Tschopp J., Harboe M. Effect of nephritic factor on C3 and on the terminal pathway of complement in vivo and in vitro. Clinical and Experimental Immunology 1986, 65:73-79.
42. Pangburn M.K. Analysis of the natural polymeric forms of human properdin and their functions in complement activation. Journal of Immunology 1989, 142:202-207.
43. Pangburn M.K. Host recognition and target differentiation by factor H, a regulator of the alternative pathway of complement. Immunopharmacology 2000, 49:149-157.
44. Pangburn M.K., Muller-Eberhard H.J. Initiation of the alternative complement pathway due to spontaneous hydrolysis of the thioester of C3. Annals of the New York Academy of Sciences 1983, 421:291-298.
45. Pangburn M.K., Muller-Eberhard H.J. The C3 convertase of the alternative pathway of human complement. Enzymic properties of the bimolecular proteinase. Biochemical Journal 1986, 235:723-730.
46. Pangburn M.K., Rawal N. Structure and function of complement C5 convertase enzymes. Biochemical Society Transactions 2002, 30:1006-1010.
47. Pickering M.C., Cook H.T., Warren J., Bygrave A.E., Moss J., Walport M.J., Botto M. Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H. Nature Genetics 2002, 31:424-428.
48. Pillemer L., Blum L., Lepow I.H., Ross O.A., Todd E.W., Wardlaw A.C. The properdin system and immunity. I. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena. Science 1954, 120:279-285.
49. Ram S., Cullinane M., Blom A.M., Gulati S., McQuillen D.P., Monks B.G., O'Connell C., Boden R., Elkins C., Pangburn M.K., Dahlback B., Rice P.A. Binding of C4b-binding protein to porin: a molecular mechanism of serum resistance of Neisseria gonorrhoeae. Journal of Experimental Medicine 2001, 193:281-295.
50. Ram S., McQuillen D.P., Gulati S., Elkins C., Pangburn M.K., Rice P.A. Binding of complement factor H to loop 5 of porin protein 1A: a molecular mechanism of serum resistance of nonsialylated Neisseria gonorrhoeae. Journal of Experimental Medicine 1998, 188:671-680.
51. Rawal N., Pangburn M. Formation of high-affinity C5 convertases of the alternative pathway of complement. Journal of Immunology 2001, 166:2635-2642.
52. Rawal N., Pangburn M.K. C5 convertase of the alternative pathway of complement. Kinetic analysis of the free and surface-bound forms of the enzyme. Journal of Biological Chemistry 1998, 273:16828-16835.
53. Rawal N., Pangburn M.K. Functional role of the noncatalytic subunit of complement C5 convertase. Journal of Immunology 2000, 164:1379-1385.
54. Rawal N., Pangburn M.K. Structure/function of C5 convertases of complement. International Immunopharmacology 2001, 1:415-422.
55. Ruseva M.M., Vernon K.A., Lesher A.M., Schwaeble W.J., Youssif M.A., Botto M., Cook H.T., Song W.C., Stover C.M., Pickering M.C. Loss of properdin exacerbates C3 glomerulopathy resulting from factor H deficiency. Journal of the American Society of Nephrology 2013, 24:43-52.
56. Schmidt C.Q., Herbert A.P., Hocking H.G., Uhrin D., Barlow P.N. Translational mini-review series on complement factor H: structural and functional correlations for factor H. Clinical and Experimental Immunology 2008, 151:14-24.
57. Schwaeble W.J., Reid K.B. Does properdin crosslink the cellular and the humoral immune response?. Immunology Today 1999, 20:17-21.
58. Servais A., Fremeaux-Bacchi V., Lequintrec M., Salomon R., Blouin J., Knebelmann B., Grunfeld J.P., Lesavre P., Noel L.H., Fakhouri F. Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome. Journal of Medical Genetics 2007, 44:193-199.
59. Servais A., Noel L.H., Roumenina L.T., Le Quintrec M., Ngo S., Dragon-Durey M.A., Macher M.A., Zuber J., Karras A., Provot F., Moulin B., Grunfeld J.P., Niaudet P., Lesavre P., Fremeaux-Bacchi V. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney International 2012, 82:454-464.
60. Sethi S., Fervenza F.C., Zhang Y., Nasr S.H., Leung N., Vrana J., Cramer C., Nester C.M., Smith R.J. Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement. Clinical Journal of the American Society of Nephrology 2011, 6:1009-1017.
61. Smith R.J., Harris C.L., Pickering M.C. Dense deposit disease. Molecular Immunology 2011, 48:1604-1610.
62. Spitzer D., Mitchell L.M., Atkinson J.P., Hourcade D.E. Properdin can initiate complement activation by binding specific target surfaces and providing a platform for de novo convertase assembly. Journal of Immunology 2007, 179:2600-2608.
63. Stover C.M., Luckett J.C., Echtenacher B., Dupont A., Figgitt S.E., Brown J., Mannel D.N., Schwaeble W.J. Properdin plays a protective role in polymicrobial septic peritonitis. Journal of Immunology 2008, 180:3313-3318.
64. Strobel S., Zimmering M., Papp K., Prechl J., Jozsi M. Anti-factor B autoantibody in dense deposit disease. Molecular Immunology 2010, 47:1476-1483.
65. Tanuma Y., Ohi H., Hatano M. Two types of C3 nephritic factor: properdin-dependent C3NeF and properdin-independent C3NeF. Clinical Immunology and Immunopathology 1990, 56:226-238.
66. Thompson R.A., Winterborn M.H. Hypocomplementaemia due to a genetic deficiency of beta 1H globulin. Clinical and Experimental Immunology 1981, 46:110-119.
67. Varade W.S., Forristal J., West C.D. Patterns of complement activation in idiopathic membranoproliferative glomerulonephritis, types I, II, and III. American Journal of Kidney Diseases 1990, 16:196-206.
68. Wirthmueller U., Dewald B., Thelen M., Schafer M.K., Stover C., Whaley K., North J., Eggleton P., Reid K.B., Schwaeble W.J. Properdin, a positive regulator of complement activation, is released from secondary granules of stimulated peripheral blood neutrophils. Journal of Immunology 1997, 158:4444-4451.
69. Xiao H., Schreiber A., Heeringa P., Falk R.J., Jennette J.C. Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. American Journal of Pathology 2007, 170:52-64.
70. Xu C., Mao D., Holers V.M., Palanca B., Cheng A.M., Molina H. A critical role for murine complement regulator crry in fetomaternal tolerance. Science 2000, 287:498-501.
71. Xu W., Berger S.P., Trouw L.A., de Boer H.C., Schlagwein N., Mutsaers C., Daha M.R., van Kooten C. Properdin binds to late apoptotic and necrotic cells independently of C3b and regulates alternative pathway complement activation. Journal of Immunology 2008, 180:7613-7621.
72. Yamasaki R., Koshino H., Kurono S., Nishinaka Y., McQuillen D.P., Kume A., Gulati S., Rice P.A. Structural and immunochemical characterization of a Neisseria gonorrhoeae epitope defined by a monoclonal antibody 2C7; the antibody recognizes a conserved epitope on specific lipo-oligosaccharides in spite of the presence of human carbohydrate epitopes. Journal of Biological Chemistry 1999, 274:36550-36558.
73. Zaferani A., Vives R.R., van der Pol P., Hakvoort J.J., Navis G.J., van Goor H., Daha M.R., Lortat-Jacob H., Seelen M.A., van den Born J. Identification of tubular heparan sulfate as a docking platform for the alternative complement component properdin in proteinuric renal disease. Journal of Biological Chemistry 2011, 286:5359-5367.
74. Zaferani A., Vives R.R., van der Pol P., Navis G.J., Daha M.R., van Kooten C., Lortat-Jacob H., Seelen M.A., van den Born J. Factor h and properdin recognize different epitopes on renal tubular epithelial heparan sulfate. Journal of Biological Chemistry 2012, 287:31471-31481.
75. Zhang Y., Meyer N.C., Wang K., Nishimura C., Frees K., Jones M., Katz L.M., Sethi S., Smith R.J. Causes of alternative pathway dysregulation in dense deposit disease. Clinical Journal of the American Society of Nephrology 2012, 7:265-274.
76. Zhou H.F., Yan H., Stover C.M., Fernandez T.M., Rodriguez de Cordoba S., Song W.C., Wu X.T., Schwaeble R.W., Atkinson W.J., Hourcade J.P., Pham D.E.C.T. Antibody directs properdin-dependent complement alternative pathway activation in a mouse model of abdominal aortic aneurysm. Proceedings of the National Academy of Sciences of the United States of America 2012, 109:E415-E422.